# Shenzhen Sibionics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-sibionics-co

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.sibionics.com
- Total disclosed funding: $150M
- Latest round: Series D (Dec 21, 2022)
- Investors on record: 18

## About

Established in 2015 and based in Shenzhen, China, SHENZHEN SIBIONICS CO., LTD. operates as a medical device developer that focuses on active implantable medical devices and medical artificial intelligence. The company has additional offices located in Beijing, Guangzhou and Los Angeles. The company launched diabetic retinopathy screening project in 2016. As of 2022, the company has over 400 employees and the core research team is accounted for more than 50%.

The company provides medical device and solutions for many fields such as health and chronic conditions management, disease screening, diagnostics and treatment. Its solutions aim to patients with retinitis pigmentosa, diabetes mellitus and gastrointestinal cancers. Project pipeline includes retinal prosthesis, continuous glucose monitoring and diabetic retinopathy screening. The company's R&D incubation platform includes intellectual property, enterprise resource management and quality management. The company adopts imaging artificial intelligence, big data and robotics technology. The company has 12 invention patents.

The company will put the funding towards CGM product R&D and promotion in series C3 funding.

## Funding rounds

- Series D, Dec 21, 2022, $72M — China New Town Development, Next Capital, Industrial Securities Capital, Shanghai Healthcare Capital, Kaiheng Capital
- Series C, Jan 21, 2022, $79M — CPE Funds Management, Shandong High-tech Investment Corporation, Qianhai Ark Capital, Xiamen C&D Emerging Industry Equity Investment, Jiangu Capital, Jingming Capital, China Life Capital
- Series C, Jan 4, 2021 — Source Code Capital, Riverhead Capital, Cedarlake Capital
- Series C, Dec 4, 2020 — Shandong High-tech Investment Corporation, Source Code Capital, Riverhead Capital
- Series B, Jun 1, 2018 — Huaxin Capital, Beijing PINS Medical Co., Ltd.
- Series A, Oct 20, 2017 — Zhuhai Longmen Capital Management, Huaxin Capital
- Series A, May 25, 2016 — Huaxin Capital

## Investors

- Huaxin Capital — Series A, Series B
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Beijing PINS Medical Co., Ltd. — Series B
- Shandong High-tech Investment Corporation (https://capitalatlas.ai/funds/shandong-high-tech-investment-corporation) — Series C
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series C
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series C
- Cedarlake Capital (https://capitalatlas.ai/funds/cedarlake-capital) — Series C
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series C
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series C
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series C
- Jiangu Capital (https://capitalatlas.ai/funds/jiangu-capital) — Series C
- Jingming Capital (https://capitalatlas.ai/funds/jingming-capital) — Series C
- China Life Capital — Series C
- China New Town Development — Series D
- Next Capital — Series D
- Industrial Securities Capital — Series D
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series D
- Kaiheng Capital (https://capitalatlas.ai/funds/kaiheng-capital) — Series D